Costs, Health Status and Outcomes of CAP (Community-Acquired Pneumonia)
Launched by UMC UTRECHT · Dec 18, 2008
Trial Information
Current as of June 08, 2025
Completed
Keywords
ClinConnect Summary
Within the study data on quality of life and various health and non-health resources and their costs is collected with the help of questionnaires administered at different points in time in different cohorts. Data collection is additional upon data collected in the main CAPITA trial, such as incidence data, mortality estimates, use of some health care resources, vaccine effectiveness and general background (socio-demographic) data.
In a first sub-study of CHO-CAP, the CAPITA participants are asked, via written information distributed shortly after vaccination, to fill in once-only a short ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Only participants of the CAPITA trial. Therefore the inclusion criteria as applied in CAPITA are the baseline for the current study. Additionally all participants had to be consent and had to fill in a baseline EQ-5D questionnaire
- • Additionally for CAP patients: Consent to be filling to participate as a CAP and the presence of CAP has to be confirmed by the independent adjudication committee of the main CAPITA trial
- • Additionally for controls: Consent to be filling to participate as control
- Exclusion Criteria:
- • The non-availability of a baseline EQ-5D score is an exclusion criterion for the prospectively followed cohorts (both CAP patients and controls)
- • In all stages of the study, patients have the right to withdraw their consent and stop their participation in this study.
About Umc Utrecht
UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
The Netherlands, , Netherlands
Patients applied
Trial Officials
G.Ardine de Wit, PhD
Principal Investigator
Julius Center for Health Sciences and Primary Care; UMC Utrecht
Marc J.M. Bonten, Prof., MD PhD
Principal Investigator
Julius Center for Health Sciences and Primary Care; UMC Utrecht
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials